Vinblastine sulfate

別名: NSC-49842, Vincaleukoblastine, 29060-LE 中文名稱：硫酸長(zhǎng)春堿

目錄號(hào)：S4505 Purity: 99.91%

Vinblastine sulfate抑制微管形成和nAChR活性，在無(wú)細(xì)胞實(shí)驗(yàn)的測(cè)定中，IC50為8.9 μM。Vinblastine sulfate 可誘導(dǎo)自噬和凋亡。

Vinblastine sulfate Chemical Structure

CAS: 143-67-9

規(guī)格	價(jià)格	庫(kù)存
10mM (1mL in DMSO)	794.43	現(xiàn)貨
5mg	573.88	現(xiàn)貨
25mg	2023.45	現(xiàn)貨
100mg	5545.08	現(xiàn)貨
1g	20230.26	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.91%

99.91

Vinblastine sulfate相關(guān)產(chǎn)品

相關(guān)產(chǎn)品	Puromycin 2HCl Staurosporine (STS) Oligomycin A Geldanamycin Honokiol Geneticin (G418 Sulfate) Nigericin sodium salt STZ (Streptozotocin) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III Pirarubicin Hygromycin B Roxithromycin	點(diǎn)擊展開(kāi)
相關(guān)化合物庫(kù)	激酶抑制劑庫(kù) 血管生成相關(guān)化合物庫(kù) TGF-beta/Smad信號(hào)通路庫(kù) 細(xì)胞骨架信號(hào)通路化合物庫(kù) 抗心血管疾病化合物庫(kù)	點(diǎn)擊展開(kāi)

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述	文獻(xiàn)信息
rat REF52 cells	Function assay	0.1 μM	30 mins	Induction of microtubule depolymerization in rat REF52 cells at 0.1 uM after 30 mins by fluorescence assay	23947826
K562 cell	Proliferation assay		48 h	Antiproliferative activity against human K562 cells after 48 hrs, IC50=0.001 μM	19220018
ACHN cells	Cytotoxicity assay		48 h	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay, IC50=22.7 μM	19467877
A375 cells	Cytotoxicity assay		48 h	Cytotoxicity against human A375 cells after 48 hrs by SRB assay, IC50=7.2 μM	19467877
C32 cells	Cytotoxicity assay		48 h	Cytotoxicity against human C32 cells after 48 hrs by SRB assay, IC50=3 μM	19467877
LNCAP cells	Cytotoxicity assay		48 h	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay, IC50=29.3 μM	19467877
Huh-7D12 cells	Cytotoxicity assay		48 h	Cytotoxicity against human Huh-7D12 cells after 48 hrs by SRB assay, IC50=45.6 μM	19467877
COR-L23 cells	Cytotoxicity assay		48 h	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay, IC50=45.5 μM	19467877
142BR cells	Cytotoxicity assay		48 h	Cytotoxicity against human 142BR cells after 48 hrs by SRB assay, IC50=37.6 μM	19467877
HT-29 cells	Cytotoxicity assay		48 h	Cytotoxicity against human HT-29 cells after 48 hrs by MTS assay, IC50=0.55 μM	21920762
A549 cells	Proliferation assay		48 h	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay, IC50=2.36 μM	22546674
DU145 cells	Proliferation assay		48 h	Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay, IC50=4.25 μM	22546674
SK-MEL-5 cells	Proliferation assay		48 h	Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay, IC50=1.74 μM	22546674
HepG2 cells	Proliferation assay		48 h	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay, IC50=0.16 μM	22546674
HT-29 cells	Proliferation assay		48 h	Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay, IC50=11.18 μM	22546674
MCF7 cells	Proliferation assay		48 h	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay, IC50=24.08 μM	22546674
MDA-MB-231 cells	Proliferation assay		48 h	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay, IC50=31.52 μM	22546674
HepG2 cells	Cytotoxicity assay		72 h	Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.056 μM	23708010
HepG2 cells	Cytotoxicity assay		72 h	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.019 μM	23708010
K562 cells	Cytotoxicity assay		72 h	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.016 μM	23708010
MDA-MB-231 cells	Cytotoxicity assay		72 h	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.0083 μM	23708010
MCF7 cells	Cytotoxicity assay		72 h	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.007 μM	23708010
UACC903 cells	Cytotoxicity assay		48 h	Cytotoxicity against human UACC903 cells after 48 hrs by MTS assay, IC50=1.65 μM	21920762
BxPC3 cells	Proliferation assay		48 h	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay, IC50=1.13 μM	22546674
COLO 320 human colorectal carcinoma cell line	Function assay			In vitro concentration required to kill 50% of COLO 320 human colorectal carcinoma cell line, EC50=0.08 μM	12361397
LNCaP human prostate cancer cell line	Function assay			In vitro concentration required to kill 50% of LNCaP human prostate cancer cell line, EC50=0.5 μM	12361397
K562 cell	Growth inhibition assay			In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth, IC50=0.001 μM	12852768
T47D cells	Function assay			In vitro concentration required to kill 50% of T47D human breast ductal carcinoma cell line, EC50=0.08 μM	12361397
SCL6 cells	Cytotoxicity assay			Cytotoxicity against human SCL6 cells by MTT assay, ED50=6.1 Μm	12880314
SCL9	Cytotoxicity assay			Cytotoxicity against human SCL9 cells by MTT assay, ED=5.3 μM	12880314
KATO III cells	Cytotoxicity assay			Cytotoxicity against human KATO III cells by MTT assay, ED50=6.1 μM	12880314
NUGC4 cells	Cytotoxicity assay			Cytotoxicity against human NUGC4 cells by MTT assay, ED50=5.3 μM	12880314
K562 cells	Function assay			Inhibition of tubulin polymerization in human K562 cells, IC50=0.13 μM	20546980
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

Vinblastine sulfate抑制微管形成和nAChR活性，在無(wú)細(xì)胞實(shí)驗(yàn)的測(cè)定中，IC50為8.9 μM。Vinblastine sulfate 可誘導(dǎo)自噬和凋亡。

靶點(diǎn)

nAChR ^[1]
(Adrenal Chromaffin Cells)

8.9 μM

體外研究(In Vitro)
體外研究活性	Vinblastine的平均終末半衰期為14.3小時(shí)。Vinblastine加入到新鮮分離的大鼠肝細(xì)胞，可迅速穿透到細(xì)胞當(dāng)中^[3]。Vinblastine抑制由腎上腺髓質(zhì)素誘導(dǎo)的血管生成反應(yīng)，還可引起M期阻滯^[4]。在特定濃度下，vinblastine能顯著增加微核單核細(xì)胞的數(shù)量^[2]。
細(xì)胞實(shí)驗(yàn)	細(xì)胞系	中國(guó)倉(cāng)鼠卵巢細(xì)胞(CHO)
	濃度	1% (v/v) (dissolved in DMSO)
	孵育時(shí)間	3 h
	方法	6孔細(xì)胞培養(yǎng)板，每孔細(xì)胞密度為5×10⁴ cells/mL，懸浮于3 mL培養(yǎng)基中。向其中加入vinblastine孵育3小時(shí)，生長(zhǎng)21小時(shí)后進(jìn)行后續(xù)檢測(cè)。
實(shí)驗(yàn)圖片	檢測(cè)方法	檢測(cè)指標(biāo)	實(shí)驗(yàn)圖片	PMID
	Western blot	ERK / p-ERK / Mcl-1 / Bad / Bid / Noxa p-JNK / c-Caspase-7 / c-PARP p-eIF2 GRP78		20371726
	Immunofluorescence	α-tubulin / Acetyl tubulin		30120268
	Growth inhibition assay	Cell viability		27114800

體內(nèi)研究(In Vivo)
體內(nèi)研究活性	Vinblastine作為抗癌劑被廣泛運(yùn)用，但具有一些意外的副作用^[6]。Vinblastine和RAP在低濃度下的結(jié)合使用，可在體內(nèi)得到比較滿意的抗血管形成作用^[4]。在臨床使用劑量下，vinblastine抑制CEM細(xì)胞中的微管蛋白的棕櫚?；?sup>[5]。

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06381570	Recruiting	Low-grade Glioma	Daniel Morgenstern\|The Hospital for Sick Children	March 21 2024	Early Phase 1

參考文獻(xiàn)
[1] McKay DB, et al. Proc Soc Exp Biol Med. 1993, 203(3):372-376. [2] George E. Johnson, et al. Mutat Res. 2010, 702(2):189-192. [3] Zhou XJ, et al. Eur J Drug Metab Pharmacokinet. 1990, 15(4):323-332. [4] Ribatti D, et al. Oncogene. 2003, 22(41):6458-6461. [5] Joan M. Caron, et al. Chemotherapy. 2007, 53:51-58. + 展開(kāi)

參考文獻(xiàn)

[1] McKay DB, et al. Proc Soc Exp Biol Med. 1993, 203(3):372-376.
[2] George E. Johnson, et al. Mutat Res. 2010, 702(2):189-192.
[3] Zhou XJ, et al. Eur J Drug Metab Pharmacokinet. 1990, 15(4):323-332.

[4] Ribatti D, et al. Oncogene. 2003, 22(41):6458-6461.
[5] Joan M. Caron, et al. Chemotherapy. 2007, 53:51-58.

+ 展開(kāi)

化學(xué)信息&溶解度

分子量	909.05	分子式	C₄₆H₅₈N₄O₉.H₂SO₄
CAS號(hào)	143-67-9	SDF	Download Vinblastine sulfate SDF
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1個(gè)月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 100 mg/mL ( (110.0 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開(kāi)封DMSO)

Water : 50 mg/mL (55.0 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (110.0 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開(kāi)封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑

動(dòng)物體內(nèi)配方計(jì)算器

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過(guò)程中的損耗，建議多配一只動(dòng)物的藥量）

給藥劑量 mg/kg 動(dòng)物平均體重 g 每只動(dòng)物給藥體積 μL 動(dòng)物數(shù)量只

第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過(guò)該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問(wèn)題，均可以通過(guò)撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問(wèn)題，請(qǐng)給我們留言。

* 必填項(xiàng)

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天